Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalbuphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 10/20 | 1.00 |
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalbuphine SCHEMBL4138643 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL3118641 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL3118636 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL10103725 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL13225650 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL19199045 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL16310791 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL17168336 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL21090866 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL4545390 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011009015-A1 | (+) - MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | TLR9, TLR3, TLR1 | OPRM1 17/4885OPRK1 24/4885OPRD1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.